OpenBiome   Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Cambridge MA United States (2012)

Organization Overview

First Clinical Trial
2015
NCT02403622
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Microbiome Health Research Institute | Microbiome Health Research Institute, (d/b/a OpenBiome) | OpenBiome

Active Ingredients

Drugs in Phase 2 Trials (1)

human fecal microbiota (Reybota) (13 trials)

Drugs in Phase 1 Trials (1)

autologous fecal microbiota (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alcoholism (Phase 1)

Anorexia (Phase 1)

Anorexia Nervosa (Phase 1)

Brain Diseases (Phase 1)

Disease (Phase 1)

Enterobacteriaceae Infections (Phase 1)

Fibrosis (Phase 1)

Hepatic Encephalopathy (Phase 1)

Irritable Bowel Syndrome (Phase 1)

Liver Cirrhosis (Phase 1)

Malnutrition (Phase 2)

Pouchitis (Phase 2)

Severe Acute Malnutrition (Phase 2)

Sjogren's Syndrome (Phase 1)

Sprains and Strains (Phase 2)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 14
  • # of Trial APIs: 2